Table 3.
Paclitaxel pharmacokinetic parameters from the basic and covariate (categorical and continous) population pharmacokinetic models
| Categorical relationship | |||
|---|---|---|---|
| Basic model | (final modsel) | Continuous relationship | |
| OBJF | 8727.003 | 8703.350 | 8680.895 |
| Parameters (value ± SE) | |||
| CL changing with time* | |||
| Slope (θ2) (l h−2) | 9.35 ± 7.32 | 10.0 ± 7.92 | 9.66 ± 6.95 |
| Min CL (θ1) (l h−1) | 7.64 ± 12.2 | 8.48 ± 12.9 | 8.59 ± 29.9 |
| t50 (θ4) (h) | 8.76 ± 16.4 | 9.36 ± 28.2 | 7.27 ± 102 |
| γ1 (θ3) | 2.94 ± 23.5 | 2.68 ± 30.2 | 2.12 ± 95.3 |
| Effect of zosuquidar on paclitaxel CL | |||
| Decrease with LY Cmax > 350 (µg l−1) (%) | – | 25.2 ± 12.4 | – |
| Emax (l h−1) | – | – | 5.49 ± 43.5 |
| LY Cmax50 (µg l−1) | – | – | 328 ± 15.4 |
| γ2 | – | – | 9.18 ± 129 |
| V1 (l) | 7.93 ± 14.0 | 7.95 ± 13.8 | 8.38 ± 13.0 |
| V2 (l) | 198 ± 7.78 | 196 ± 7.81 | 194 ± 16.0 |
| Q2 (l h−1) | 11.1 ± 7.37 | 10.8 ± 9.35 | 11.2 ± 11.3 |
| Q3 (l h−1) | 6.57 ± 15.8 | 6.76 ± 16.4 | 6.35 ± 39.4 |
| V3(l) | 7.00 ± 15.4 | 7.51 ± 18.9 | 10.2 ± 164 |
| ω CL (%) | 27.2 ± 33.2 | 25.9 ± 29.7 | 24.8 ± 34.3 |
| ω CL-Q2 (%) | 32.6 ± 23.4 | 30.5 ± 23.2 | 29.6 ± 24.7 |
| ω Q2 (%) | 44.5 ± 28.0 | 43.7 ± 26.1 | 43.5 ± 37.0 |
| ω CL-V2 (%) | 29.3 ± 30.7 | 26.1 ± 38.4 | 24.2 ± 39.5 |
| ω Q2-V2 (%) | 40.7 ± 29.9 | 39.6 ± 29.2 | 37.5 ± 35.1 |
| ωV2 (%) | 43.7 ± 26.6 | 42.8 ± 26.0 | 40.9 ± 31.4 |
| ωV1 (%) | 38.5 ± 58.6 | 40.0 ± 52.4 | 41.7 ± 58.6 |
| ω IOV CL (%) | 20.9 ± 33.2 | 15.2 ± 53.9 | 16.1 ± 56.2 |
| ω IOV V1 (%) | 57.5 ± 39.6 | 54.5 ± 42.8 | 46.6 ± 47.9 |
| Residual variance (%) | 22.7 ± 7.75 | 22.9 ± 7.77 | 22.5 ± 8.00 |
*
During the infusion *postinfusion 
with INF the length of the infusion and time the time from the start of the infusion.